Use the Search Fields to Find Information
Page 82 of 339
Preclinical Models of THC and Nicotine Exposure During Adolescent Brain Development: Modeling Neuropsychiatric Phenotypes Related to Dopaminergic Transmission
Please use this link to access publication Abstract Adolescence is a gradual transition period between childhood and adulthood, characterized by greater sensitivity to rewarding stimuli.
February 20, 2024
Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist
Abstract Cannabinoid receptor 2 agonists and inverse agonists are emerging as new therapeutic options for a spectrum of autoimmune-related disease. Of particular interest, is the
September 19, 2019
Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence
ABSTRACT Cannabidiol (CBD) is a constituent of the cannabis plant with a diverse array of pharmacological activities as well as potential therapeutic uses. An oral
January 29, 2024
Preclinical Assessment of Novel Therapeutics on the Cough Reflex: Cannabinoid Agonists as Potential Antitussives
Cough, a reflex defense mechanism, is a common symptom of many airway inflammatory diseases. At present there are no satisfactory treatments for cough that have
September 19, 2019
Pre-Post Cannabis Legalization for Adult Use: A Trend Study of Two Cohorts of Young Adult Cannabis Users in Los Angeles
Please use this link to access this publication. ABSTRACT Cannabis was legalized for adult use in California in 2016 for individuals 21 and older. Among
March 6, 2025
Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome
Please use this link to access this publication. ABSTRACT Introduction Pharmaceutically purified oral cannabidiol (CBD) has been recently approved by the US Food and Drug
April 19, 2024
Practical Strategies Using Medical Cannabis to Reduce Harms Associated With Long Term Opioid Use in Chronic Pain
Abstract Background: Chronic non-cancer pain (CNCP) is estimated to affect 20% of the adult population. Current United States and Canadian Chronic non-cancer pain guidelines recommend careful
June 20, 2025
Practical considerations for testing the effects of cannabidiol on human anxiety
Abstract Empirical evidence continues to accumulate suggesting cannabidiol (CBD) may have potential as an anxiolytic. Yet, research in the area is insufficient to support strong
October 28, 2021
PPARγ receptors are involved in the effects of cannabidiol on orofacial dyskinesia and cognitive dysfunction induced by typical antipsychotic in mice
Abstract Tardive dyskinesia (TD) is a movement disorder that appears after chronic use of drugs that block dopaminergic receptors such as antipsychotics. Besides the motor symptoms, patients with TD also present cognitive
April 24, 2024
Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2
Osteosarcoma is the most frequent primary malignant bone tumor that occurs in children and adolescents. The present study aimed to identify novel therapeutic strategies for
September 19, 2019
Page 82 of 339